An international study comparing conventional versus mRNA level testing (TargetPrint) for ER, PR, and HER2 status of breast cancer-Reference-Cited by-同舟云学术

An international study comparing conventional versus mRNA level testing (TargetPrint) for ER, PR, and HER2 status of breast cancer

Published:2016-07-04 Issue:3 Volume:469 Page:297-304
ISSN:0945-6317
Container-title:Virchows Archiv
language:en
Short-container-title:Virchows Arch

Author:

Wesseling Jelle,Tinterri Corrado,Sapino Anna,Zanconati Fabrizio,Lutke-Holzik Martijn,Nguyen Bichlien,Deck Kenneth B,Querzoli Patrizia,Perin Tiziana,Giardina Carmela,Seitz Gerhard,Guinebretière Jean-Marc,Barone Julie,Dekker Laura,de Snoo Femke,Stork-Sloots Lisette,Roepman Paul,Watanabe Toru,Cusumano Pino

Funder

Agendia

Publisher

Springer Science and Business Media LLC

Subject

Cell Biology,Molecular Biology,General Medicine,Pathology and Forensic Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00428-016-1979-9.pdf

Reference45 articles.

1. Febbo PG, Ladanyi M, Aldape KD, et al: NCCN task force report: evaluating the clinical utility of tumor markers in oncology. J Natl Compr Canc Netw 2011;(suppl 5):S1-S32

2. Liu S, Chia SK, Mehl E, et al. (2010) Progesterone receptor is a significant factor associated with clinical outcomes and effect of adjuvant tamoxifen therapy in breast cancer patients. Breast Cancer Res Treat 119:53–61

3. Loi S, Haibe-Kains B, Desmedt C, et al. (2008) Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen. BMC Genomics 9:239